MENU

NARI Stock Tickeron detected bullish Stock Pattern: Pennant NARI on December 04, 2024, netting in a 26.09% gain over 1 month

A.I.dvisor
at Tickeron.com
Loading...
+26.09% Gain from a Successful pattern Pennant
NARI - Inari Medical
Tickeron
Ticker: NARI
Company: Inari Medical
Gain: +26.09%
Confirmed: 12/04/24
Succeeded: 01/06/25
Total length: 34 days
On December 03, 2024, A.I.dvisor detected a Pennant Pattern (Bullish) for Inari Medical (NARI, $51.55). On December 04, 2024, A.I.dvisor confirmed the Bullish pattern, setting a target price of $62.91. 33 days later, on January 06, 2025, NARI reached the target price resulting in a +2 for traders who took a long position in the stock.

NARI's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for NARI turned positive on January 06, 2025. Looking at past instances where NARI's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 06, 2025. You may want to consider a long position or call options on NARI as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

NARI moved above its 50-day moving average on January 06, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +5 3-day Advance, the price is estimated to grow further. Considering data from situations where NARI advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NARI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NARI broke above its upper Bollinger Band on January 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NARI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.886) is normal, around the industry mean (23.475). NARI has a moderately high P/E Ratio (344.828) as compared to the industry average of (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.429) is also within normal values, averaging (41.274).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NARI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
NARI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a medical device company which develops, manufactures, markets and sells devices for the interventional treatment of venous diseases

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
6001 Oak Canyon
Phone
+1 877 923-4747
Employees
1300
Web
https://www.inarimedical.com